GTx, Inc. To Present At The Lazard Capital Markets Annual Life Sciences Conference

MEMPHIS, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- GTx, Inc., , the Men's Health Biotech Company, announced today that it will present at the Lazard Capital Markets Annual Life Sciences Conference on Tuesday, November 29, 2005, at 10:30 a.m. Eastern Standard Time at the New York Palace Hotel. The presentation will be simultaneously webcast, and can be accessed on the company's website at http://www.gtxinc.com.

Dr. Mitchell S. Steiner, CEO of GTx, will present an overview of the company's clinical development and discovery programs.

An archived replay of the presentation will be available on the company's website until December 13, 2005.

About GTx

GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx, headquartered in Memphis, Tenn., currently has four clinical programs. GTx is developing ACAPODENE (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: (1) a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer and (2) a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with the pre-cancerous prostate lesion called high grade prostatic intraepithelial neoplasia, also known as high grade PIN. In its third clinical program, GTx is developing ostarine for the treatment of wounds and acute muscle wasting conditions in burn patients and plans to initiate a Phase II clinical trial for ostarine for this indication in the fourth quarter of 2005. GTx is also evaluating clinical development of ostarine for the treatment of chronic muscle wasting conditions, such as testosterone deficiency in aging men, or andropause. In its fourth clinical program, GTx and its partner, Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, are developing andarine, another one of GTx's SARMs, for the treatment of cancer cachexia. GTx is working with Ortho Biotech to plan a Phase II clinical trial of andarine.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that (i) GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not be able to obtain required regulatory approvals to commercialize its product candidates; (iii) GTx's clinical trials may not be completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx's prospectus supplement filed with the U.S. Securities and Exchange Commission (the "SEC") pursuant to Rule 424(b)(5) on October 12, 2005, contains under the heading "Risk Factors," a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

CONTACT: McDavid Stilwell, Manager, Corporate Communications & FinancialAnalysis of GTx, Inc., +1-901-523-9700

Web site: http://www.gtxinc.com/